1. Home
  2. SILO

as of 05-15-2026 3:57pm EST

$0.41
+$0.02
+4.75%
Stocks Consumer Discretionary Apparel Nasdaq

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

Founded: 2010 Country:
United States
United States
Employees: N/A City: SARASOTA
Market Cap: 7.2M IPO Year: 2011
Target Price: N/A AVG Volume (30 days): 1.4M
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: annual
EPS: -0.12 EPS Growth: 57.98
52 Week Low/High: $0.22 - $1.01 Next Earning Date: 05-13-2026
Revenue: $72,102 Revenue Growth: N/A
Revenue Growth (this year): 1.86% Revenue Growth (next year): N/A
P/E Ratio: -3.38 Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered SILO Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 71.26%
71.26%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: